1
|
Cao Y, Wang Z, Song W, Liu Y, Zhao Q, Li W, Zheng C, Li W, Chen Z, Zhu L, Duan T, Li X. Perilla frutescens: A new strategy for uranium decorporation. Chemosphere 2024; 350:141066. [PMID: 38159731 DOI: 10.1016/j.chemosphere.2023.141066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/25/2023] [Revised: 12/15/2023] [Accepted: 12/28/2023] [Indexed: 01/03/2024]
Abstract
Radionuclide uranium is a great threat to human health, due to its high chemical toxicity and radioactivity. Finding suitable uranium decorporation to reduce damage caused by uranium internal contamination is an important aspect of nuclear emergency response. However, the poor selectivity and/or high toxicity of the only excretory promoter approved by Food and Drug Administration (FDA) is an obvious disadvantage. Herein, we choose an edible natural product, the traditional Chinese medicine called Perilla frutescens (PF), which has wide sources and can be used as an excellent and effective uranyl decorporation. In vivo uranium decorporation assays illustrate the removal efficiency of uranium in kidney were 68.87% and 43.26%, in femur were 56.66% and 54.53%, by the test of prophylactic and immediate administration, respectively. Cell level experiments confirmed that it had better biocompatibility than CaNa3-DTPA (CaNa3-diethylenetriamine pentaacetate, a commercial actinide excretion agent). In vitro static adsorption experiments exhibited that its excellent selectivity sorption for uranyl. All those results findings would provide new research insights about natural product for uranyl decorporation.
Collapse
Affiliation(s)
- Yalan Cao
- School of Life Sciences and Engineering, Southwest University of Science and Technology, Mianyang, 629000, China; National Co-Innovation Center for Nuclear Waste Disposal and Environmental Safety, Southwest University of Science and Technology, Mianyang, 621010, China; State Key Laboratory of Environment-friendly Energy Materials, Southwest University of Science and Technology, Mianyang, 621010, China
| | - Zeru Wang
- National Co-Innovation Center for Nuclear Waste Disposal and Environmental Safety, Southwest University of Science and Technology, Mianyang, 621010, China; State Key Laboratory of Environment-friendly Energy Materials, Southwest University of Science and Technology, Mianyang, 621010, China
| | - Wanrong Song
- National Co-Innovation Center for Nuclear Waste Disposal and Environmental Safety, Southwest University of Science and Technology, Mianyang, 621010, China; State Key Laboratory of Environment-friendly Energy Materials, Southwest University of Science and Technology, Mianyang, 621010, China
| | - Yawen Liu
- National Co-Innovation Center for Nuclear Waste Disposal and Environmental Safety, Southwest University of Science and Technology, Mianyang, 621010, China; State Key Laboratory of Environment-friendly Energy Materials, Southwest University of Science and Technology, Mianyang, 621010, China
| | - Qian Zhao
- National Co-Innovation Center for Nuclear Waste Disposal and Environmental Safety, Southwest University of Science and Technology, Mianyang, 621010, China; State Key Laboratory of Environment-friendly Energy Materials, Southwest University of Science and Technology, Mianyang, 621010, China
| | - Wenhao Li
- National Co-Innovation Center for Nuclear Waste Disposal and Environmental Safety, Southwest University of Science and Technology, Mianyang, 621010, China; State Key Laboratory of Environment-friendly Energy Materials, Southwest University of Science and Technology, Mianyang, 621010, China
| | - Caohui Zheng
- National Co-Innovation Center for Nuclear Waste Disposal and Environmental Safety, Southwest University of Science and Technology, Mianyang, 621010, China; State Key Laboratory of Environment-friendly Energy Materials, Southwest University of Science and Technology, Mianyang, 621010, China
| | - Wenshuang Li
- National Co-Innovation Center for Nuclear Waste Disposal and Environmental Safety, Southwest University of Science and Technology, Mianyang, 621010, China; State Key Laboratory of Environment-friendly Energy Materials, Southwest University of Science and Technology, Mianyang, 621010, China
| | - Zhengguo Chen
- NHC Key Laboratory of Nuclear Technology Medical Transformation (MIANYANG CENTRAL HOSPITAL), Mianyang, 621000, China
| | - Lin Zhu
- National Co-Innovation Center for Nuclear Waste Disposal and Environmental Safety, Southwest University of Science and Technology, Mianyang, 621010, China; Tianfu Institute of Research and Innovation, Southwest University of Science and Technology, Chengdu, 610299, China; State Key Laboratory of Environment-friendly Energy Materials, Southwest University of Science and Technology, Mianyang, 621010, China.
| | - Tao Duan
- National Co-Innovation Center for Nuclear Waste Disposal and Environmental Safety, Southwest University of Science and Technology, Mianyang, 621010, China; NHC Key Laboratory of Nuclear Technology Medical Transformation (MIANYANG CENTRAL HOSPITAL), Mianyang, 621000, China.
| | - Xiaoan Li
- NHC Key Laboratory of Nuclear Technology Medical Transformation (MIANYANG CENTRAL HOSPITAL), Mianyang, 621000, China.
| |
Collapse
|
2
|
Martínez-Alonso B, Torres Pabón NS, Fernández-Bachiller MI, Durán GT, Crespo RG, Torrado-Salmerón CF, Sánchez AJ, Peña Fernández MÁ. Physicochemical and pharmacotechnical characterization of Prussian blue for future Prussian blue oral dosage forms formulation. Heliyon 2024; 10:e24284. [PMID: 38293450 PMCID: PMC10824789 DOI: 10.1016/j.heliyon.2024.e24284] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2023] [Revised: 01/03/2024] [Accepted: 01/05/2024] [Indexed: 02/01/2024] Open
Abstract
Ferric hexacyanoferrate, Fe4 [Fe(CN)6]3 · xH2O, known as Prussian blue (PB), has proven its effectiveness as an antidote in cases of accidental poisoning or poisoning caused by radioactive materials such as cesium (Cs) and thallium (Tl); which due to their solubility in water, when absorbed by the human body, cause serious damage to vital organs. The local development of a drug with PB as an active ingredient arises as a response to the civil and military needs established within the Ministry's pharmacy request for national defense. This fact contemplates the circumstances related to public health protection in the nuclear, radiological, biological and chemical (NRBQ) of the emergency institutions in health and national security. In this paper and by using various analytical techniques, the characterization of the locally synthesized PB with pharmaceutical quality has been described, as a first step to predict its behavior in the preparation of a drug that contains it as an active ingredient. The research findings demonstrate that locally synthesized PB is suitable for use in oral dosage forms, enabling the local development of drug formulations incorporating PB, thus being able to potentially become a main resource in the treatment of Cs and Tl poisoning in any accidental or intended of the population. This development opens up the possibility of creating drug formulations that incorporate PB at a local level, making it a potentially significant resource in the treatment of Cs and Tl poisoning. The ability to locally produce and utilize PB in oral dosage forms could be crucial in addressing cases of accidental or intentional exposure within the population. This advancement not only contributes to the scientific understanding of PB but also holds promising implications for practical applications in public health and emergency situations.
Collapse
|
3
|
Kastl M, Grémy O, Lamart S, Giussani A, Li WB, Hoeschen C. Modelling DTPA therapy following Am contamination in rats. Radiat Environ Biophys 2023; 62:483-495. [PMID: 37831188 PMCID: PMC10628027 DOI: 10.1007/s00411-023-01046-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/14/2023] [Accepted: 09/25/2023] [Indexed: 10/14/2023]
Abstract
A major challenge in modelling the decorporation of actinides (An), such as americium (Am), with DTPA (diethylenetriaminepentaacetic acid) is the fact that standard biokinetic models become inadequate for assessing radionuclide intake and estimating the resulting dose, as DTPA perturbs the regular biokinetics of the radionuclide. At present, most attempts existing in the literature are empirical and developed mainly for the interpretation of one or a limited number of specific incorporation cases. Recently, several approaches have been presented with the aim of developing a generic model, one of which reported the unperturbed biokinetics of plutonium (Pu), the chelation process and the behaviour of the chelated compound An-DTPA with a single model structure. The aim of the approach described in this present work is the development of a generic model that is able to describe the biokinetics of Am, DTPA and the chelate Am-DTPA simultaneously. Since accidental intakes in humans present many unknowns and large uncertainties, data from controlled studies in animals were used. In these studies, different amounts of DTPA were administered at different times after contamination with known quantities of Am. To account for the enhancement of faecal excretion and reduction in liver retention, DTPA is assumed to chelate Am not only in extracellular fluids, but also in hepatocytes. A good agreement was found between the predictions of the proposed model and the experimental results for urinary and faecal excretion and accumulation and retention in the liver. However, the decorporation from the skeletal compartment could not be reproduced satisfactorily under these simple assumptions.
Collapse
Affiliation(s)
- Manuel Kastl
- Institute of Radiation Medicine, Helmholtz Center Munich, German Research Center for Environmental Health, Neuherberg, Germany.
| | - Olivier Grémy
- Laboratoire de Radio Toxicologie, CEA, Université de Paris-Saclay, Arpajon, France
| | - Stephanie Lamart
- Laboratoire de Radio Toxicologie, CEA, Université de Paris-Saclay, Arpajon, France
- Laboratoire d'Evaluation de la Dose Interne, Institut de Radioprotection et de Sûreté Nucléaire (IRSN), PSE-SANTE/SDOS/LEDI, Fontenay-aux-Roses, France
| | - Augusto Giussani
- Division of Medical and Occupational Radiation Protection, Federal Office for Radiation Protection, Oberschleißheim, Germany
| | - Wei Bo Li
- Institute of Radiation Medicine, Helmholtz Center Munich, German Research Center for Environmental Health, Neuherberg, Germany
- Division of Medical and Occupational Radiation Protection, Federal Office for Radiation Protection, Oberschleißheim, Germany
| | - Christoph Hoeschen
- Institut für Medizintechnik, Otto-Von-Guericke University Magdeburg, Magdeburg, Germany
| |
Collapse
|
4
|
Grémy O, Devilliers K, Miccoli L. Chelation therapy with 3,4,3-Li(1,2-HOPO) after pulmonary exposure to plutonium in rats. Chem Biol Interact 2023; 378:110488. [PMID: 37054935 DOI: 10.1016/j.cbi.2023.110488] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2023] [Revised: 04/04/2023] [Accepted: 04/11/2023] [Indexed: 04/15/2023]
Abstract
Internal exposure to plutonium can occur through inhalation for the nuclear worker, but also for the public if the radionuclide was released into the atmosphere in the context of a nuclear accident or terrorist attack. DieThylenetriaminePentaAcetic acid (DTPA) is currently still the only authorized chelator that can be used to decorporate internalized plutonium. The Linear HydrOxyPyridinOne-based ligand named 3,4,3-Li(1,2-HOPO) remains the most promising drug candidate to replace it in the hopes of improving chelating treatment. This study aimed to assess the efficacy of 3,4,3-Li(1,2-HOPO) in removing plutonium from rats exposed to the lungs, depending on the timing and route of treatment, and almost always compared to DTPA at a ten-fold higher dose used as a reference chelator. First, early intravenous injection or inhalation of 3,4,3-Li(1,2-HOPO) demonstrated superior efficacy over DTPA in preventing plutonium accumulation in liver and bone in rats exposed by injection or lung intubation. However, this superiority of 3,4,3-Li(1,2-HOPO) was much less pronounced with delayed treatment. In rats given plutonium in the lungs, the experiments also showed that 3,4,3-Li-HOPO reduced pulmonary retention of plutonium more effectively than DTPA only when the chelators were injected early but not at delayed times, while it was always the better of the two chelators when they were inhaled. Under our experimental conditions, the rapid oral administration of 3,4,3-Li(1,2-HOPO) was successful in preventing systemic accumulation of plutonium, but not in decreasing lung retention. Thus, after exposure to plutonium by inhalation, the best emergency treatment would be the rapid inhalation of a 3,4,3-Li(1,2-HOPO) aerosol to limit pulmonary retention of plutonium and prevent extrapulmonary deposition of plutonium in target systemic tissues.
Collapse
Affiliation(s)
- Olivier Grémy
- Laboratoire de RadioToxicologie, Commissariat à l'Energie Atomique et aux Energies Alternatives, Université de Paris-Saclay, Bruyères-le-Châtel, France.
| | - Karine Devilliers
- Laboratoire de RadioToxicologie, Commissariat à l'Energie Atomique et aux Energies Alternatives, Université de Paris-Saclay, Bruyères-le-Châtel, France
| | - Laurent Miccoli
- Laboratoire de RadioToxicologie, Commissariat à l'Energie Atomique et aux Energies Alternatives, Université de Paris-Saclay, Bruyères-le-Châtel, France
| |
Collapse
|
5
|
Agrawal V, Sandal N, Singh AK, Pathak DP. pH dependent release matrix oral formulation of prussian blue to improve its efficacy as internal decorporation agent. Curr Drug Deliv 2021; 18:1162-1173. [PMID: 33504305 DOI: 10.2174/1567201818666210127093327] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2020] [Revised: 11/02/2020] [Accepted: 12/11/2020] [Indexed: 11/22/2022]
Abstract
BACKGROUND Prussian Blue (PB) is available as conventional release dosage form "Radiogardase" with effective daily dose 3-10 g (very high). The target site is duodenum where it inhibits enterohepatic circulation of Cs & Tl ions, enhancing their fecal excretion. OBJECTIVE To enhance efficacy, target release, reduce dose and side effects, oral pH dependent matrix formulation of PB based on in-situ gelation of sodium alginate along with calcium salts was formulated and evaluated. METHODS Different combinations of matrix granules were formulated and optimized. The optimized one was compressed using Polyvinylpyrrolidone K30 (Pvp K30) in different batches and optimized. Langmuir adsorption isotherm was used to assess in-vitro binding efficacy of formulation to thallium using atomic absorption spectroscopy. The proof of concept i.e. drug release in duodenum was studied through pharmacoscintigraphy using radiolabeled formulation in rabbits. RESULTS The optimized granules showed no drug release in acidic medium for 2 h whereas complete empty of basket in basic medium within 30-60 minutes. The matrix tablet formulation with Pvp K30 (10% w/w) was optimized with desired hardness and optimum in-vitro release profile. The release data fitted to various linear kinetic models, Hixson-Crowell r2 (0.9906) best fit, confirmed the erosion based release mechanism. The maximum binding capacity (MBC) was found significantly higher (89.60 mg Tl/g formulation) than that of PB API (65.90 mg Tl /g PB API). Pharmacoscintigraphic images confirmed intact formulation in stomach up to 2h and burst release in intestine thereafter. CONCLUSION The results exemplify oral pH dependent PB matrix formulation which achieved desirable target release at duodenum and in-vitro binding efficacy towards Tl ion was appreciable.
Collapse
Affiliation(s)
- Vaishali Agrawal
- Institute of Nuclear Medicine and Allied Sciences, Defence Research and Development Organization, New Delhi. India
| | - Nidhi Sandal
- Institute of Nuclear Medicine and Allied Sciences, Defence Research and Development Organization, New Delhi. India
| | - Ajay K Singh
- Institute of Nuclear Medicine and Allied Sciences, Defence Research and Development Organization, New Delhi. India
| | - Dharam Pal Pathak
- Delhi Institute of Pharmaceutical Sciences and Research, New Delhi. India
| |
Collapse
|
6
|
Garai A, Delangle P. Recent advances in uranyl binding in proteins thanks to biomimetic peptides. J Inorg Biochem 2019; 203:110936. [PMID: 31864150 DOI: 10.1016/j.jinorgbio.2019.110936] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2019] [Revised: 11/05/2019] [Accepted: 11/17/2019] [Indexed: 12/29/2022]
Abstract
Uranium is an element belonging to the actinide series. It is ubiquitous in rock, soil, and water. Uranium is found in the ecosystem due to mining and milling industrial activities and processing to nuclear fuel, but also to the extensive use of phosphate fertilizers. Understanding uranium binding in vivo is critical, first to deepen our knowledge of molecular events leading to chemical toxicity, but also to provide new mechanistic information useful for the development of efficient decorporation treatments to be applied in case of intoxication. The most stable form in physiological conditions is the uranyl cation (UO22+), in which uranium oxidation state is +VI. This short review presents uranyl coordination properties and chelation, and what is currently known about uranium binding to proteins. Although several target proteins have been identified, the UO22+ binding sites have barely been identified. Biomimetic approaches using model peptides are good options to shed light on high affinity uranyl binding sites in proteins. A strategy based on constrained cyclodecapeptides allowed recently to propose a tetraphosphate binding site for uranyl that provides an affinity similar to the one measured with the phosphoprotein osteopontin.
Collapse
Affiliation(s)
- Aditya Garai
- Univ. Grenoble Alpes, CEA, CNRS, IRIG, SyMMES, F-38000 Grenoble, France
| | - Pascale Delangle
- Univ. Grenoble Alpes, CEA, CNRS, IRIG, SyMMES, F-38000 Grenoble, France.
| |
Collapse
|
7
|
Yan TT, Lin GA, Wang MJ, Lamkowski A, Port M, Rump A. Pharmacological treatment of inhalation injury after nuclear or radiological incidents: The Chinese and German approach. Mil Med Res 2019; 6:10. [PMID: 30961671 PMCID: PMC6454727 DOI: 10.1186/s40779-019-0200-2] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/11/2018] [Accepted: 03/25/2019] [Indexed: 12/20/2022] Open
Abstract
Inhalation injury is often associated with burns and significantly increases morbidity and mortality. The main toxic components of fire smoke are carbon monoxide, hydrogen cyanide, and irritants. In the case of an incident at a nuclear power plant or recycling facility associated with fire, smoke may also contain radioactive material. Medical treatments may vary in different countries, and in this paper, we discuss the similarities and differences in the treatments between China and Germany. Carbon monoxide poisoning is treated by 100% oxygen administration and, if available, hyperbaric oxygenation in China as well as in Germany. In addition, antidotes binding the cyanide ions and relieving the respiratory chain are important. Methemoglobin-forming agents (e.g., nitrites, dimethylaminophenol) or hydroxocobalamin (Vitamin B12) are options. The metabolic elimination of cyanide may be enhanced by sodium thiosulfate. In China, sodium nitrite with sodium thiosulfate is the most common combination. The use of dimethylaminophenol instead of sodium nitrite is typical for Germany, and hydroxocobalamin is considered the antidote of choice if available in cases of cyanide intoxications by fire smoke inhalation as it does not further reduce oxygen transport capacity. Systematic prophylactic use of corticosteroids to prevent toxic pulmonary edema is not recommended in China or Germany. Stable iodine is indicated in the case of radioiodine exposure and must be administered within several hours to be effective. The decorporation of metal radionuclides is possible with Ca (DTPA) or Prussian blue that should be given as soon as possible. These medications are used in both countries, but it seems that Ca (DTPA) is administered at lower dosages in China. Although the details of the treatment of inhalation injury and radionuclide(s) decorporation may vary, the general therapeutic strategy is very similar in China and Germany.
Collapse
Affiliation(s)
- Tian-Tian Yan
- Military Burn Center, the 990th Hospital of the Joint Logistics Support Forces of Chinese PLA (the 159th Hospital of Chinese PLA), Zhumadian, 463000, Henan, China.
| | - Guo-An Lin
- Military Burn Center, the 990th Hospital of the Joint Logistics Support Forces of Chinese PLA (the 159th Hospital of Chinese PLA), Zhumadian, 463000, Henan, China
| | - Min-Jie Wang
- Military Burn Center, the 990th Hospital of the Joint Logistics Support Forces of Chinese PLA (the 159th Hospital of Chinese PLA), Zhumadian, 463000, Henan, China
| | | | - Matthias Port
- Bundeswehr Institute of Radiobiology, Munich, Germany
| | - Alexis Rump
- Bundeswehr Institute of Radiobiology, Munich, Germany
| |
Collapse
|
8
|
Yue YC, Li MH, Wang HB, Zhang BL, He W. The toxicological mechanisms and detoxification of depleted uranium exposure. Environ Health Prev Med 2018; 23:18. [PMID: 29769021 PMCID: PMC5956823 DOI: 10.1186/s12199-018-0706-3] [Citation(s) in RCA: 44] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2018] [Accepted: 04/30/2018] [Indexed: 01/03/2023] Open
Abstract
Depleted uranium (DU) has been widely applied in industrial and military activities, and is often obtained from producing fuel for nuclear reactors. DU may be released into the environment, polluting air, soil, and water, and is considered to exert both radiological and chemical toxicity. In humans and animals, DU can induce multiple health effects, such as renal tubular necrosis and bone malignancies. This review summarizes the known information on DU’s routes of entry, mechanisms of toxicity, and health effects. In addition, we survey the chelating agents used in ameliorating DU toxicity.
Collapse
Affiliation(s)
- Yong-Chao Yue
- Department of Chemistry, School of Pharmacy, Fourth Military Medical University, No. 169 Changle West Road, Xi'an, 710032, Shaanxi, People's Republic of China
| | - Ming-Hua Li
- Department of Chemistry, School of Pharmacy, Fourth Military Medical University, No. 169 Changle West Road, Xi'an, 710032, Shaanxi, People's Republic of China
| | - Hai-Bo Wang
- Department of Chemistry, School of Pharmacy, Fourth Military Medical University, No. 169 Changle West Road, Xi'an, 710032, Shaanxi, People's Republic of China
| | - Bang-Le Zhang
- Department of Pharmaceutics, School of Pharmacy, Fourth Military Medical University, No. 169 Changle West Road, Xi'an, 710032, Shaanxi, People's Republic of China.
| | - Wei He
- Department of Chemistry, School of Pharmacy, Fourth Military Medical University, No. 169 Changle West Road, Xi'an, 710032, Shaanxi, People's Republic of China.
| |
Collapse
|
9
|
Andersen O, Aaseth J. A review of pitfalls and progress in chelation treatment of metal poisonings. J Trace Elem Med Biol 2016; 38:74-80. [PMID: 27150911 DOI: 10.1016/j.jtemb.2016.03.013] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/17/2016] [Revised: 03/14/2016] [Accepted: 03/17/2016] [Indexed: 01/31/2023]
Abstract
Most acute and chronic human metal poisonings are due to oral or inhalation exposure. Almost 80% of published animal experiments on chelation in metal poisoning used single or repeated intraperitoneal, intramuscular or intravenous administration of metal and chelator, impeding extrapolation to clinical settings. Intramuscular administration of dimercaptopropanol (BAL) has until now been used in acute arsenic, lead, and mercury poisonings, but repeated BAL administration increased the brain uptake of As, Pb and Hg in experimental animals. Also, diethyl dithiocarbamate (DDC) has been used as antidote in acute experimental animal parenteral Cd poisoning, and both DDC and tetraethylthiuram disulfide (TTD, disulfiram, Antabuse) have been used in nickel allergic patients. However, even one dose of DDC given immediately after oral Cd or Ni increased their brain uptake considerably. The calcium salt of ethylenediamminetetraacetic acid (CaEDTA) but not dimercaptosuccinic acid (DMSA) increased the brain uptake of Pb. In oral Cd or Hg poisoning, early oral administration of DMSA or dimercaptopropane sulfonate (DMPS) increased survival and reduced intestinal metal uptake. Oral administration of Prussian Blue or resins with fixed chelating groups that are not absorbed offer chelation approaches for decorporation after oral exposure to various metals. Diethylenetriaminepentaacetic acid (DTPA) nebulizers for pulmonary chelation after inhalation exposure need further development. Also, combined chelation with more than one compound may offer extensive advances. Solid knowledge on the chemistry of metal chelates together with relevant animal experiments should guide development of chelation procedures to alleviate and not aggravate the clinical status of poisoned patients.
Collapse
Affiliation(s)
- Ole Andersen
- Roskilde University, Roskilde, Denmark, Denmark.
| | - Jan Aaseth
- Innlandet Hospital Trust and Hedmark University College, Elverum, Norway, Norway
| |
Collapse
|
10
|
Prybylski JP, Semelka RC, Jay M. Can gadolinium be re-chelated in vivo? Considerations from decorporation therapy. Magn Reson Imaging 2016; 34:1391-3. [PMID: 27530538 DOI: 10.1016/j.mri.2016.08.001] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2016] [Accepted: 08/07/2016] [Indexed: 02/06/2023]
Abstract
Gadolinium (Gd) and Gd-based contrast agents (GBCAs) have been observed to deposit in tissues of patients following contrast enhanced MR imaging procedures. A conservative approach for chelation therapy of this toxic metal dictates the assumption that minimal intact GBCAs are present. Currently the extent to which these deposits are primarily de-chelated Gd remains uncertain, prevailing knowledge suggests that for linear agents much of the Gd is de-chelated, while for the macrocyclic agents, the Gd may be still largely chelated. To extract Gd from tissues and facilitate its release, chelation therapy should be both safe and effective. Here we discuss chelation therapy as it relates to Gd deposition. The principles of chelation are reviewed, initially with reference to ligand stability in complex biological fluids. A model of decorporation and how it relates to elimination of Gd deposits is also reviewed. When more is learned about Gd deposition, optimal removal strategies must be developed using basic thermodynamic and kinetic principles.
Collapse
|
11
|
Fattal E, Tsapis N, Phan G. Novel drug delivery systems for actinides (uranium and plutonium) decontamination agents. Adv Drug Deliv Rev 2015; 90:40-54. [PMID: 26144994 DOI: 10.1016/j.addr.2015.06.009] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2015] [Revised: 06/18/2015] [Accepted: 06/24/2015] [Indexed: 12/17/2022]
Abstract
The possibility of accidents in the nuclear industry or of nuclear terrorist attacks makes the development of new decontamination strategies crucial. Among radionuclides, actinides such as uranium and plutonium and their different isotopes are considered as the most dangerous contaminants, plutonium displaying mostly a radiological toxicity whereas uranium exhibits mainly a chemical toxicity. Contamination occurs through ingestion, skin or lung exposure with subsequent absorption and distribution of the radionuclides to different tissues where they induce damaging effects. Different chelating agents have been synthesized but their efficacy is limited by their low tissue specificity and high toxicity. For these reasons, several groups have developed smart delivery systems to increase the local concentration of the chelating agent or to improve its biodistribution. The aim of this review is to highlight these strategies.
Collapse
|